NOVO NORDISK A/S revenue for the last year amounted to 28.95 B CHF, the most of which — 26.81 B CHF — came from its highest performing source at the moment, Diabetes and Obesity Care, the year earlier bringing 20.76 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought NOVO NORDISK A/S 15.89 B CHF, and the year before that — 11.23 B CHF.